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Background: New treatment methods have challenged open surgery as a treatment for great saphenous
vein (GSV) insufficiency, the most common being ultrasound-guided foam sclerotherapy (UGFS) and
endovenous laser ablation (EVLA). This study evaluated the long-term results of surgery, EVLA and
UGFS in the treatment of GSV reflux.
Methods: Patients with symptomaticGSV refluxwere randomized to undergo either open surgery, EVLA
or UGFS. The main outcome measure was the occlusion rate of the GSV at 5 years after operation.
Results: The study included 196 patients treated during 2008–2010; of these, 166 (84⋅7 per cent)
participated in the 5-year follow-up. At 5 years, the GSV occlusion rate was 96 (95 per cent c.i. 91 to
100) per cent in the open surgery group, 89 (82 to 98) per cent after EVLA and 51 (38 to 64) per cent
after UGFS (P<0⋅001). For patients who had received no additional treatment during follow-up, the
occlusion rates were 96 per cent (46 of 48), 89 per cent (51 of 57) and 41 per cent (16 of 39) respectively.
UGFS without further GSV treatment was successful in only 16 of 59 patients (27 per cent) at 5 years.
Conclusion: UGFS has significantly inferior occlusion rates compared with open surgery or EVLA, and
results in additional treatments.
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Introduction
Varicose veins affect up to 40 per cent of the adult pop-
ulation, causing symptoms that affect quality of life. The
most common manifestations result from reflux of the
great saphenous vein (GSV)1. There are many methods
of treating GSV reflux: open surgery, foam sclerother-
apy (UGFS), and endovenous catheter ablation using, for
example, radiofrequency or laser energy. Although newer,
less invasive endovenous techniques have replaced open
surgery at many clinics, data on their long-term efficiency
have so far been scarce2–4. An RCT5 comparing these
three methods in the treatment of unilateral GSV reflux
was carried out at two university hospitals in Finland dur-
ing 2008–2010. One year after the treatment, GSV reflux
was significantly more common in theUGFS group than in
the other two treatment groups. However, disease-specific
quality of life was significantly better after 1 year compared
with baseline in all treatment groups, with no significant
difference between the groups. Similarly, varicose veins
were absent in all groups at 1 year5.
The aim of the present study was to report 5-year
follow-up results of this RCT comparing open surgery,
endovenous laser ablation (EVLA) and UGFS in the treat-
ment of GSV reflux, in terms of both technical success and
quality of life.
Methods
The study protocol, methods, and the 1-month and
1-year results have been described in detail previously5.
Briefly, patients aged 20–70 years, with Clinical Etiologic
Anatomic Pathophysiologic (CEAP) class C2–C4 varicose
veins, and reflux in the GSV 5–10mm in diameter were
included. The final study population initially comprised
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214 patients: 65 in the surgery group, 73 in the EVLA
group and 76 in the UGFS group.
All patients from the RCT treated at Helsinki Univer-
sity Hospital were invited to attend a 5-year follow-up
visit. The follow-up data for patients from Tampere Uni-
versity Hospital were not available. The Ethics Commit-
tee of Helsinki University Central Hospital approved this
follow-up study. All patients had providedwritten informed
consent for follow-up visits at the start of the trial.
Procedures
In the open surgery procedure, the GSV was stripped with
a retrograde invagination technique, usually down to the
upper calf. Most patients were treated under general anaes-
thesia. Tumescent liquid (450ml Ringer’s solution with
50ml 1 per cent lidocaine with adrenaline (epinephrine))
was injected into the tunnel of the removed GSV as well
as the hook phlebectomy sites after stripping. A class 2
compression stocking and bandages were applied for 48 h,
with stocking use continued during the daytime for up to
2weeks.
Tumescent anaesthesia was also used for EVLA; patients
received a light sedative before (diazepam) and during
(alfentanil, propofol) the procedure. In most patients, the
surgeon inserted the laser catheter into the upper calf and,
under ultrasound guidance, positioned the tip 1⋅5–2⋅0 cm
below the saphenofemoral junction. A pulse mode with a
1⋅5-s impulse and 12Wof energy was used, aiming to apply
70 J/cm. Phlebectomies and after care were similar to those
in the surgery group.
In the UGFS group, the surgeon cannulated the GSV,
usually both at proximal thigh level and immediately
below the knee. Sclerosant foam was prepared with a
double-syringe technique using a sclerosant-to-air ratio of
1 : 2 using either 1 per cent polidocanol (Aetoxysclerol®;
Kreussler, Wiesbaden, Germany) or 1 and 3 per cent
sodium tetradecyl sulphate (Fibrovein™; STD Pharma-
ceutical Products, Hereford, UK). A compression stocking
was applied afterwards to be worn continuously for 3 days,
followed by daytime use for 11 days. All patients attended
an appointment at 1month and, if any reflux was observed
on duplex imaging, a second treatment with foam was car-
ried out, followed by a check-up 1month later until the
GSV was occluded.
Assessments
For this study, the patients were invited for examination
5 years after treatment. Assessments included a duplex
ultrasound examination, clinical outcome evaluation, and
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Fig. 1 Study flow chart. GSV, great saphenous vein
disease-specific quality-of-life measurement using the
Aberdeen Varicose Vein Severity Score (AVVSS)6. The
closure of the GSV was classified as follows: absent/fully
occluded, partial recanalization (at least 5 cm of com-
pressible, patent GSV), or complete recanalization. Reflux
was defined as a retrograde flow lasting more than 0⋅5 s
after calf compression. The leg was also imaged for other
refluxing veins, such as the anterior accessory saphe-
nous vein (AASV). Neovascularization was defined by
non-anatomical serpentine refluxing veins that entered the
common femoral vein at the saphenofemoral junction. At
both 1- and 5-year follow-up, if the patient had symptoms
and either a recanalized GSV, a new refluxing venous
segment such as the AASV, or neovascularization, they
were assigned for additional treatment. The method of the
additional treatment was decided by the treating physician.
Statistical analysis
Data were evaluated by means of intention-to-treat analy-
sis, but excluding missing data. The primary endpoint for
the entire study, occlusion or absence of the GSV, was ana-
lysed in the overall study group and the three subgroups
according to the initial size of the upper GSV.
Categorical values were compared using the χ2 or Fisher’s
exact test, and numerical data using the Kruskal–Wallis
test or linear regression, where applicable. Statistical ana-
lysis, including life-table analysis, was performed using
SPSS® for Windows® version 22.0 (IBM, Armonk, New
York, USA).
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Table 1 Baseline characteristics of patients included in the follow-up study
Open surgery (n=50) EVLA (n=57) UGFS (n=59) P†
Age (years)* 46⋅5(10⋅2) 47⋅7(13⋅4) 48⋅6(12⋅0) 0⋅601
BMI (kg/m2)* 24⋅6(3⋅6) 25⋅4(3⋅5) 25⋅8(4⋅9) 0⋅379
Diameter of thigh GSV (mm)* 6⋅2(1⋅1) 6⋅3(1⋅1) 6⋅2(1⋅2) 0⋅515
CEAP class 0⋅085‡
C2 29 19 21
C3 17 29 30
C4 4 9 8
Clinical disability score 0⋅882‡
0 (symptomless) 1 1 0
1 (symptoms, no compression) 37 42 39
2 (work only with compression) 12 14 20
3 (not working even with compression) 0 0 0
4 (hospital care) 0 0 0
Side treated
Right leg 21 30 21
Left leg 29 27 38
*Values are mean(s.d.). EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy; GSV, great saphenous vein; CEAP, Clinical
Etiologic Anatomic Pathophysiologic. †Kruskal–Wallis test, except ‡χ2 test.
Results
Of 196 patients initially treated atHelsinkiUniversityHos-
pital, 166 (84⋅7 per cent) attended for 5-year follow-up:
50 after open surgery, 57 after EVLA and 59 after UGFS
(Fig. 1). This represented 77⋅6 per cent of the origi-
nal study cohort (patients treated in Tampere were not
included). Median follow-up was 5 years and 99 days (range
1485–2456 days) after treatment. Baseline clinical details
in these patients were similar in all treatment groups
(Table 1).
At 5 years, the GSVwas completely occluded or absent in
48 of 50 patients in the surgery group (96 (95 per cent c.i.
91 to 100) per cent, 51 of 57 patients who had EVLA (89
(82 to 98) per cent) and in 30 of 59 patients who underwent
UGFS (51 (38 to 64) per cent) (Fig. 2). The difference
between the UGFS group and the EVLA or surgery group
was statistically significant (P< 0⋅001).
At 5 years, there were no significant differences in the
GSV occlusion rate according to initial sizes of the GSV, as
analysed in three size groups (under 6, 6–9 and over 9mm;
P= 0⋅290).
The mean AVVSS score at 5 years was 8⋅7 (95 per cent
c.i. 6⋅7 to 10⋅7) in the surgery group, 9⋅6 (6⋅4 to 12⋅8)
in the EVLA group and 11⋅2 (8⋅5 to 14⋅0) in the UGFS
group. Although the mean AVVSS was slightly higher after
UGFS, the differences between the treatment groups were
not statistically significant (P= 0⋅636).
By 5 years after surgery, a total of 22 patients had already
received further treatment for the GSV: two (4 per cent)
in the surgery group, none in the EVLA group and 20 (34
per cent) in the UGFS group. A subanalysis of non-assisted
closure of the GSV (including only patients who had not
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Fig. 2 Great saphenous vein (GSV) occlusion rates after
treatment. EVLA, endovenous laser ablation; UGFS,
ultrasound-guided foam sclerotherapy
received repeat treatment for the GSV) therefore included
48 patients in the surgery group, 57 in the EVLA group
and 39 in the UGFS group.
Non-assisted closure of the GSV occurred at 5 years in
46 of the 48 patients (96 per cent) in the surgery group, 51
of 57 (89 per cent) in the EVLA group and 16 of 39 (41 per
cent) in the UGFS group. Primary and assisted occlusion
rates are depicted in life tables (Fig. 3).
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Fig. 3 Life-table analysis of a primary occlusion rates and b assisted occlusion rates after treatment. EVLA, endovenous laser ablation;
UGFS, ultrasound-guided foam sclerotherapy
Other outcomes
Of the 166 patients, 48 (28⋅9 per cent) either needed
retreatment during follow-up or were assigned for retreat-
ment at the 5-year visit. The odds of needing repeat treat-
ment was 8⋅5 times higher for theUGFS group than for the
EVLA group, and 1⋅6 times higher for the surgery group
compared with the EVLA group.
Many patients in the UGFS group needed additional
treatment for the GSV (Table 2). Two patients in the
surgery group needed further treatment for the GSV;
these represented incomplete stripping. In six patients in
the EVLA group, either partial or full recanalization of
the GSV occurred during follow-up. These patients had
received a mean of 45⋅4 (range 20⋅7–66⋅1) J of laser energy
per treated cm of GSV compared with 54⋅7 (19⋅7–85⋅4)
J/cm among those with an occluded GSV at 5 years
(P= 0⋅150). In general, there was no statistically signif-
icant correlation between the energy (J/cm) and 5-year
outcomes of no reflux and absence of repeat treatments
(P= 0⋅143). Of the six patients mentioned, three had
partial recanalization of the GSV with no symptoms. The
other three had complete recanalization, one of whom was
symptomatic and received retreatment.
Two patients in the surgery group also had reflux
originating from neovascularization in the groin. In the
Table 2 Additional treatment in each study group
Open surgery
(n=50)
EVLA
(n=57)
UGFS
(n= 59)
Additional treatment
scheduled or done
9 7 32
Repeat treatment for GSV 2 1 25
Additional treatment for
anterior accessory
saphenous vein
0 4 3
Additional treatment for
neovascularized segments
2 0 0
Additional treatment for
under-knee GSV or
tributaries
5 2 4
EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam
sclerotherapy; GSV, great saphenous vein.
EVLA group, four patients received treatment for a
refluxing AASV.
Altogether, 22 patients in the UGFS group who attended
the 5-year follow-up had experienced either full or par-
tial recanalization of the GSV at 1 year, but had no symp-
toms at that point. Three of the 16 patients with partial
recanalization had already been retreated during follow-up
and six were scheduled for EVLA at the 5-year follow-up
visit, as the recanalization had become complete. One of
the six patients with full recanalization had been treated
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during follow-up and three were scheduled for treatment
at the 5-year follow-up. The remaining patients were
symptom-free.
There were no major complications related to the proce-
dures, and long-term side-effects were rare. At the 5-year
follow-up, two patients (4 per cent) in the open surgery
group, one (2 per cent) in the EVLA group and two (4
per cent) in the UGFS group still had skin pigmenta-
tion. One patient treated with open surgery had a palpable
lump under the skin. Paraesthesia was rare (1⋅8 per cent),
with no differences between the treatment groups (1 in
each group).
Discussion
Achieving good long-term freedom from recurrent super-
ficial venous insufficiency after the treatment of GSV reflux
is challenging. Less invasive techniques have replaced open
surgery in many places owing to the faster recovery from
the procedure.
There are several ways to categorize the success of vari-
cose vein treatment. Patients who have partial or com-
plete recanalization of the GSV after the initial treatment
may remain asymptomatic and do not necessarily need
additional treatment. However, here it seems that many
did need retreatment. It was far more likely that patients
treated initially with UGFS needed additional treatments,
especially repeated treatment for the main GSV trunk.
Therefore, although UGFS was initially the cheapest and
most non-invasive treatment, it may have become more
invasive and more expensive in the end.
At 1 year, the initial size of the GSV and its occlusion
rate were correlated5. This was not observed at 5 years,
probably because patients with a large, refluxing GSV had
already been retreated at that point.
In all groups, the AVVSS scores at 1 year had improved
significantly from baseline. This improvement was sus-
tained during follow-up. The differences between the
three groups in terms of quality of life at 5 years did not
reach statistical significance, although there was a tendency
towards higher scores indicating lower quality of life in the
UGFS group.
The nature of additional treatments also reflected the
technique used. As described by van Rij and colleagues7,
open surgery can lead to neovascularization from the groin.
This occurs because angiogenesis is a natural part of wound
healing, and can appear even after a 5-year interval8. In the
present study, several patients in the open surgery group
needed treatment for neovascular segments, but there were
no patients with neovascularization after EVLA, similar to
reports on EVLA from others9.
When treating the GSV with EVLA, it is normal pol-
icy to leave the tip of the laser fiber 1–2 cm below the
saphenofemoral junction. Therefore, any GSV tributaries
that drain above that point are untreated. Frequently, the
AASV remains open after EVLA. The AASV reflux that
occurs after EVLA is thought to represent either neo-
reflux or failure to demonstrate the reflux during the
pretreatment ultrasound examination. In the present study,
the rate of AASV reflux after EVLA treatment was 7 per
cent. The result supports the current practice of not treat-
ing the AASV if only GSV reflux is present10.
There are studies suggesting that UGFS is a good option,
although most of the data come from prospective series
or retrospective analyses11–14. In many of these studies,
the anatomical success rate (occlusion or absence of the
GSV) is not very good, although patient satisfaction may
be high. Recently published randomized trials comparing
open surgery, EVLA and UGFS had quality of life or
cost-effectiveness as endpoints, and evaluated UGFS to be
a viable treatment option15,16. In these studies, however,
follow-up was short.
It is argued that, in very skilled hands, UGFS might pro-
duce excellent results. In the present study, however, UGFS
was administered by experienced vascular surgeons accord-
ing to the best of their knowledge and ability, and repeated
until the vein was seen to be fully occluded, making the
procedure as effective as possible. However, after this,
patients were not followed further. They later attended
the 1-year follow-up visit, where reflux was observed in
half of the patients. More frequent visits and an active
refoaming policy in the presence of any reflux may have
increased the occlusion rate in the long run, but would,
again, have required more resources. Furthermore, as most
of the patients were young, every visit would have meant
a day off work. The present results reflect those seen in
the real world. It is easier to standardize the EVLA pro-
cedure than UGFS, with EVLA having very repeatable
results and a steep learning curve. Therefore, EVLA prob-
ably gives better results than UGFS in most clinical prac-
tice settings. EVLA can be administered as an outpatient,
reducing the number of staff and materials required, thus
making it cost-effective.
There are some limitations to the present study. Owing
to the nature of the interventions, neither the patients nor
the treating surgeons could be blinded to the intervention.
The application of foam was not standardized, but optimal
injection sites and sclerosants were used for each patient
according to their anatomy. The assessor at the 5-year
follow-up was not blinded to the type of treatment; in
the majority of patients, the scarring pattern would have
revealed it. Some crossover occurred but, as the main
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results were analysed by intention to treat, this effect was
minimized. Only patients who had unilateral GSV reflux
on one side only participated in the study. This makes
the results more reliable when considering the subjective
experience of the patient.
Some patients were assigned for additional treatment at
the 5-year follow-up visit. All of them had symptomatic
recurrent venous disease. Many of these patients reported
that they had already been about to obtain a referral for
retreatment before they received the invitation to attend
the follow-up visit. However, it could be argued that the
rate of additional treatments was increased because of the
follow-up visit, and some patients would not have sought
additional treatment without it.
EVLA is a safe and effective means of treating GSV
reflux, and the results are durable. It has a slightly lower rate
of additional treatments needed afterwards than surgery.
UGFS, in contrast, produced anatomical success without
further GSV treatment at 5 years in only 27 per cent of
the patients (16 of 59); patients in the UGFS group needed
more repeat treatments. Primary GSV reflux is best treated
with either open surgery or an endothermal ablation such
as EVLA. UGFS should be considered as a valid treatment
option for those with recurrent varicose veins or incompe-
tent tributary veins, but its value in treating primary GSV
reflux is low.
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